An update from Cocrystal Pharma ( (COCP) ) is now available.
On April 24, 2025, Cocrystal Pharma announced that its norovirus oral antiviral candidate, CDI-988, demonstrated potent activity against the emerging GII.17 norovirus variants, which have become more prevalent than the GII.4 strain in recent years. The company reported favorable safety and tolerability results from a Phase 1 study and plans to initiate a human challenge study in 2025 to further evaluate CDI-988 as a potential treatment and prevention for norovirus infection. This development positions Cocrystal Pharma as a significant player in addressing the urgent need for effective norovirus treatments, potentially impacting the industry by offering a first-in-class oral antiviral solution.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma’s financial challenges, including zero revenue and ongoing losses, heavily weigh down its stock score. Technical indicators are bearish, and the negative P/E ratio further reflects valuation concerns. While the new equity incentive plan is a positive corporate event, it does not substantially improve the outlook given the financial and technical pressures.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication process of noroviruses, influenza viruses, coronaviruses, and hepatitis C viruses. The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
YTD Price Performance: -39.09%
Average Trading Volume: 21,732
Technical Sentiment Signal: Buy
Current Market Cap: $14.15M
See more data about COCP stock on TipRanks’ Stock Analysis page.